Physician profile
Devjit Halder
NPI 1962677666
$5,652.49
in general payments reported to CMS, 2019-2025
29 companies · $740 in 2025
The $740 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,649 · 2020: $194 · 2021: $224 · 2022: $823 · 2023: $1,106 · 2024: $917 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,762.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,153.55 | 2022-2024 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $634.46 | 2019-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $515.77 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $484.96 | 2019-2020 | |
| Corcept Therapeutics | $354.74 | 2024-2025 | Korlym |
| Esperion Therapeutics, INC. | $235.58 | 2021-2024 | Nexletol, Nexlizet |
| Sanofi-Aventis U.S. LLC | $211.12 | 2022-2024 | |
| Abbvie INC. | $193.51 | 2021-2023 | |
| Gilead Sciences, INC. | $189.88 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.47 | 2021-2025 | Xifaxan |
| Terumo Bct, INC. | $145.44 | 2019 | |
| Jazz Pharmaceuticals INC. | $141.80 | 2022 | |
| Daiichi Sankyo INC. | $122.08 | 2019 | |
| Ibsa Pharma INC. | $119.57 | 2024 | Tirosint |
| Alcresta Therapeutics, INC. | $119.54 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $110.57 | 2019 | |
| Exactech, INC. | $104.41 | 2019 | |
| Boston Scientific Corporation | $98.64 | 2019 | |
| Pfizer INC. | $98.43 | 2024 | |
| Greenwich Biosciences, INC. | $88.19 | 2019 | |
| Xeris Pharmaceuticals, INC. | $82.41 | 2023 | Gvoke Hypopen |
| Abiomed | $60.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $58.31 | 2021 | |
| Medtronic, INC. | $41.25 | 2021-2023 | Intellis Adaptivestim |
| Organogenesis INC. | $39.34 | 2023 | Puraply |
| Biohaven Pharmaceuticals, INC. | $23.33 | 2021 | |
| Phadia US INC. | $21.01 | 2021 | |
| Inogen, INC. | $15.77 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Dexcom, INC. | $12.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devjit Halder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.